Clinical Study

A031702- A Phase II Study Of Ipilimumab , Cabozantinib, And Nivolumab In Rare Genitourinary Cancers (Iconic)

Posted Date: Jan 18, 2021

  • Investigator: Shuchi Gulati
  • Specialties: Cancer, Kidney Disease, Oncology
  • Type of Study: Drug

The main purpose of this study is to evaluate the efficacy of cabozantinib s-malate (cabozantinib) combined with nivolumab and ipilimumab in the first or second-line (and beyond) setting for patients within each of the rare genitourinary (GU) variant histology group of interest, as measured by objective response rate (ORR).


To Be Eligible: Must Have Diagnosis Of A Metastatic Rare Gu Cancer, Be Able To Swallow Oral Tablets, Adequate Organ Function, No Chemo Or Radiation Within 2 Weeks, No Evidence Of Tumor Invading Gi Tract Or Major Blood Vessels, No Uncontrolled, Significant Intercurrent Or Recent Illness Or Infection That May Impact Safety On The Study


Genitourinary Cancers, Gu, Rare

For More Information:

Uc Cancer Center

  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at or (513) 245-3417.